ExodusPoint Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

ExodusPoint Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,800	Closed	-$274K	–	1553
2026 Q1	$274K	Buy	+6,800	New	+$147K	﹤0.01%	1332

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ExodusPoint Capital Management's APLS Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 62,989 shares — an estimated $2.53M sold.

ExodusPoint Capital Management first reported a position in APLS in Q3 2020 and held it in 12 quarters. The position peaked at $5.48M in Q1 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

ExodusPoint Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 62,989 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.53M.
ExodusPoint Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 12 quarters.
ExodusPoint Capital Management's Apellis Pharmaceuticals position peaked at $5.48M in Q1 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.